hsa‑miR‑17‑5p: A Possible Predictor of Ombitasvir/Paritaprevir/ Ritonavir+Dasabuvir±Ribavirin Therapy Efcacy in Hepatitis C Infection

Zehra Öksüz | Enver Üçbilek | Mehmet Sami Serin | Serkan Yaraş | Gülhan Örekici | Temel Orhan Sezgin

Although persistent sustained viral response rates are increased in hepatitis C infection following administration of direct acting antiviral (DAA) agents, the pre-use predictive parameters of these antivirals and the clinical progression in patients post-treatment remain unknown. To obtain data pertaining to the predictive parameters prior to the use of ombitavir/paritaprevir/ritonavir+dasabuvir and the clinical progression in patients following antiviral treatment. The expression profles of miR-223-3p, miR-17-5p, miR-24-3p, and TLR2 − 196 to − 174 del/ins polymorphisms from the blood/serum of 34 hepatitis C virus (HCV)-infected patients pre- and post-ombitavir/paritaprevir/ritonavir+dasabuvir treatment were determined by RT-qPCR. The expression levels of miR-17-5p (P0.05); neverthe...